Current status of and future prospects for the treatment of unresectable or metastatic gastrointestinal stromal tumours

[1]  Robin L. Jones,et al.  Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  A. Sawaki,et al.  Pimitespib in patients with advanced gastrointestinal stromal tumor (CHAPTER-GIST-301): a randomized, double-blind, placebo-controlled phase 3 trial. , 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  M. Heinrich,et al.  A phase 1, multicenter, open-label, first-in-human study of DS-6157a in patients (pts) with advanced gastrointestinal stromal tumor (GIST). , 2022, Journal of Clinical Oncology.

[4]  M. Heinrich,et al.  New treatment strategies for advanced-stage gastrointestinal stromal tumours , 2022, Nature Reviews Clinical Oncology.

[5]  L. Qin,et al.  Phase Ib Trial of the Combination of Imatinib and Binimetinib in Patients with Advanced Gastrointestinal Stromal Tumors , 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

[6]  N. Schultz,et al.  Phase II Trial of Imatinib Plus Binimetinib in Patients With Treatment-Naive Advanced Gastrointestinal Stromal Tumor , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Robin L. Jones,et al.  Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study , 2021, Clinical cancer research : an official journal of the American Association for Cancer Research.

[8]  S. Hirota,et al.  Pimitespib is effective on cecal GIST in a mouse model of familial GISTs with KIT-Asp820Tyr mutation through KIT signaling inhibition. , 2021, Experimental and molecular pathology.

[9]  S. Sleijfer,et al.  Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  Christian M. Metallo,et al.  Establishment of Patient-Derived Succinate Dehydrogenase–Deficient Gastrointestinal Stromal Tumor Models for Predicting Therapeutic Response , 2021, Clinical Cancer Research.

[11]  R. DeMatteo,et al.  A Randomized Phase II Study of Nivolumab Monotherapy or Nivolumab Combined with Ipilimumab in Patients with Advanced Gastrointestinal Stromal Tumors , 2021, Clinical Cancer Research.

[12]  Robin L. Jones,et al.  Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  B. Rubin,et al.  Inhibition of PI3K and MAPK pathways along with KIT inhibitors as a strategy to overcome drug resistance in gastrointestinal stromal tumors , 2021, PloS one.

[14]  A. Shields,et al.  Association of Combination of Conformation-Specific KIT Inhibitors With Clinical Benefit in Patients With Refractory Gastrointestinal Stromal Tumors: A Phase 1b/2a Nonrandomized Clinical Trial. , 2021, JAMA oncology.

[15]  T. Nishida,et al.  Recent Progress and Challenges in the Diagnosis and Treatment of Gastrointestinal Stromal Tumors , 2021, Cancers.

[16]  C. Serrano,et al.  A phase Ib/II study of selinexor in combination with imatinib in patients with advanced gastrointestinal stromal tumor (GIST): SeliGIST/GEIS-41 trial. , 2021 .

[17]  J. Blay,et al.  Gastrointestinal stromal tumours , 2009 .

[18]  G. Demetri,et al.  Identification and Therapeutic Targeting of GPR20, Selectively Expressed in Gastrointestinal Stromal Tumors, with DS-6157a, a First-In-Class Antibody-Drug Conjugate. , 2021, Cancer discovery.

[19]  Robin L. Jones,et al.  Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial , 2021, European journal of cancer.

[20]  C. Kelly,et al.  The management of metastatic GIST: current standard and investigational therapeutics , 2021, Journal of Hematology & Oncology.

[21]  M. Karamouzis,et al.  Gastrointestinal Stromal Tumors (GISTs): Novel Therapeutic Strategies with Immunotherapy and Small Molecules , 2021, International journal of molecular sciences.

[22]  J. Sicklick,et al.  NCCN Guidelines Insights: Soft Tissue Sarcoma, Version 1.2021. , 2020, Journal of the National Comprehensive Cancer Network : JNCCN.

[23]  P. Rutkowski,et al.  1667TiP A phase II, single arm study of avelumab in combination with axitinib in patients with unresectable/metastatic gastrointestinal stromal tumor after failure of standard therapy - AXAGIST , 2020 .

[24]  G. Demetri,et al.  Abstract 5181: Therapeutic targeting of GPR20, selectively expressed in gastrointestinal stromal tumor (GIST), with DS-6157a, an antibody-drug conjugate (ADC) , 2020 .

[25]  Robin L. Jones,et al.  Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial. , 2020, The Lancet. Oncology.

[26]  Sohita Dhillon.  Ripretinib: First Approval , 2020, Drugs.

[27]  Robin L. Jones,et al.  Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial. , 2020, The Lancet. Oncology.

[28]  Sohita Dhillon.  Avapritinib: First Approval , 2020, Drugs.

[29]  DS-6157a in Participants With Advanced Gastrointestinal Stromal Tumor (GIST) , 2020, Case Medical Research.

[30]  FDA approves avapritinib for gastrointestinal stromal tumor with a rare mutation , 2020, Case Medical Research.

[31]  S. Hirota,et al.  TAS-116 inhibits oncogenic KIT signalling on the Golgi in both imatinib-naïve and imatinib-resistant gastrointestinal stromal tumours , 2019, British Journal of Cancer.

[32]  J. Sicklick,et al.  Current management of succinate dehydrogenase–deficient gastrointestinal stromal tumors , 2019, Cancer and Metastasis Reviews.

[33]  J. Fletcher,et al.  Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours , 2019, British Journal of Cancer.

[34]  E. Calleja,et al.  First-in-Human Phase I Study of an Oral HSP90 Inhibitor, TAS-116, in Patients with Advanced Solid Tumors , 2019, Molecular Cancer Therapeutics.

[35]  Robin L. Jones,et al.  Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[36]  A. D. Dei Tos,et al.  Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression with imatinib, sunitinib and regorafenib , 2018, Therapeutic advances in medical oncology.

[37]  Jung-Han Kim,et al.  Stereotactic Core-Needle Biopsy of Non-Mass Calcifications: Outcome and Accuracy at Long-Term Follow-Up , 2003, Korean journal of radiology.

[38]  P. Meltzer,et al.  A phase II trial of the DNA methyl transferase inhibitor, SGI-110 (guadecitabine), in children and adults with wild type GIST, pheochromocytoma and paraganglioma associated with succinate dehydrogenase deficiency and HLRCC-associated kidney cancer. , 2018 .

[39]  J. Blay,et al.  Dovitinib in patients with gastrointestinal stromal tumour refractory and/or intolerant to imatinib , 2017, British Journal of Cancer.

[40]  J. Carles,et al.  Novel Insights into the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors , 2017, Targeted Oncology.

[41]  P. Nederlof,et al.  Clinical characteristics and treatment outcome in a large multicentre observational cohort of PDGFRA exon 18 mutated gastrointestinal stromal tumour patients. , 2017, European journal of cancer.

[42]  I. Judson,et al.  UK clinical practice guidelines for the management of gastrointestinal stromal tumours (GIST) , 2017, Clinical Sarcoma Research.

[43]  L. Qin,et al.  Combined KIT and CTLA-4 Blockade in Patients with Refractory GIST and Other Advanced Sarcomas: A Phase Ib Study of Dasatinib plus Ipilimumab , 2016, Clinical Cancer Research.

[44]  C. Antonescu,et al.  PD-1/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors , 2016, Clinical Cancer Research.

[45]  J. Bendell,et al.  A Phase 2 Study of the Hsp90 Inhibitor AUY922 as Treatment for Patients with Refractory Gastrointestinal Stromal Tumors , 2016, Cancer investigation.

[46]  G. Demetri,et al.  Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour. , 2016, European journal of cancer.

[47]  S. Hirota,et al.  Asian Consensus Guidelines for the Diagnosis and Management of Gastrointestinal Stromal Tumor , 2016, Cancer research and treatment : official journal of Korean Cancer Association.

[48]  H. Joensuu,et al.  Radiotherapy for GIST progressing during or after tyrosine kinase inhibitor therapy: A prospective study. , 2015, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[49]  J. Doroshow,et al.  Phase I study of the heat shock protein 90 (Hsp90) inhibitor onalespib (AT13387) administered on a daily for 2 consecutive days per week dosing schedule in patients with advanced solid tumors , 2015, Investigational New Drugs.

[50]  K. Kihara,et al.  Heat shock protein 90 targeting therapy: state of the art and future perspective , 2015, EXCLI journal.

[51]  S. Ohkubo,et al.  TAS-116, a Highly Selective Inhibitor of Heat Shock Protein 90α and β, Demonstrates Potent Antitumor Activity and Minimal Ocular Toxicity in Preclinical Models , 2014, Molecular Cancer Therapeutics.

[52]  G. Shapiro,et al.  First-in-Human Phase I Dose Escalation Study of a Second-Generation Non-Ansamycin HSP90 Inhibitor, AT13387, in Patients with Advanced Solid Tumors , 2014, Clinical Cancer Research.

[53]  J. Watanabe,et al.  Phase I dose-escalation study of the HSP90 inhibitor AUY922 in Japanese patients with advanced solid tumors , 2014, Cancer Chemotherapy and Pharmacology.

[54]  H. Cao,et al.  Is there a role of surgery in patients with recurrent or metastatic gastrointestinal stromal tumours responding to imatinib: a prospective randomised trial in China. , 2014, European journal of cancer.

[55]  H. Kindler,et al.  Considering the role of radiation therapy for gastrointestinal stromal tumor , 2014, OncoTargets and therapy.

[56]  T. Nishida,et al.  Impact of Rechallenge with Imatinib in Patients with Advanced Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib , 2014, Gastroenterology research and practice.

[57]  G. Demetri,et al.  Amulticenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors ( GIST ) following failure of at least imatinib and sunitinib , 2013 .

[58]  G. Demetri,et al.  Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial. , 2013, The Lancet. Oncology.

[59]  Heikki Joensuu,et al.  Gastrointestinal stromal tumour , 2013, The Lancet.

[60]  Xiaoyan Chen,et al.  Phase I study of the safety, pharmacokinetics and antitumor activity of famitinib , 2013, Cancer Chemotherapy and Pharmacology.

[61]  L. Paz-Ares,et al.  Inhibition of HSP90 molecular chaperones: moving into the clinic. , 2013, The Lancet. Oncology.

[62]  J. Blay,et al.  Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial , 2013, The Lancet.

[63]  C. Antonescu,et al.  Phase II study of the HSP90-inhibitor BIIB021 in gastrointestinal stromal tumors. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[64]  M. Heinrich,et al.  Gastrointestinal stromal tumours: origin and molecular oncology , 2011, Nature Reviews Cancer.

[65]  J. Fletcher,et al.  An open-label phase II study of the Hsp90 inhibitor ganetespib (STA-9090) in patients (pts) with metastatic and/or unresectable GIST. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  Robin L. Jones,et al.  Radiofrequency ablation is a feasible therapeutic option in the multi modality management of sarcoma. , 2010, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[67]  C. Antonescu,et al.  NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. , 2010, Journal of the National Comprehensive Cancer Network : JNCCN.

[68]  D. Solís.  US Food and Drug Administration , 2010 .

[69]  K. Ahrar,et al.  Hepatic Arterial Embolization and Chemoembolization for Imatinib-Resistant Gastrointestinal Stromal Tumors , 2009, American journal of clinical oncology.

[70]  S. Hirota,et al.  Secondary mutations in the kinase domain of the KIT gene are predominant in imatinib‐resistant gastrointestinal stromal tumor , 2008, Cancer science.

[71]  J. Crowley,et al.  Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[72]  J. Lasota,et al.  Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. , 2009, Archives of pathology & laboratory medicine.

[73]  K. Ahrar,et al.  Hepatic artery chemoembolization for 110 gastrointestinal stromal tumors , 2006, Cancer.

[74]  Xin Huang,et al.  Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial , 2006, The Lancet.

[75]  J. Blay,et al.  KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. , 2006, European journal of cancer.

[76]  S. Lindquist,et al.  HSP90 and the chaperoning of cancer , 2005, Nature Reviews Cancer.

[77]  C. Antonescu,et al.  Acquired Resistance to Imatinib in Gastrointestinal Stromal Tumor Occurs Through Secondary Gene Mutation , 2005, Clinical Cancer Research.

[78]  P. Marynen,et al.  Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. , 2005, Gastroenterology.

[79]  S. Hirota,et al.  Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. , 2003, Gastroenterology.

[80]  Samuel Singer,et al.  PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors , 2003, Science.

[81]  P S Meltzer,et al.  Gastrointestinal stromal tumors with KIT mutations exhibit a remarkably homogeneous gene expression profile. , 2001, Cancer research.

[82]  S. Hirota,et al.  Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. , 1998, Science.

[83]  M. Ferrarini,et al.  Unusual expression and localization of heat‐shock proteins in human tumor cells , 1992, International journal of cancer.

[84]  E. Atkinson,et al.  Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. Implications for surgical management and staging. , 1992, Annals of surgery.